28 recruiting, 19 completed, 13 terminated, 11 active not recruiting. 30 Phase 1, 29 Phase 2, 12 Not applicable, 4 Phase 3, 2 Early Phase 1.
Follow Cutaneous Melanoma: new trials by email Literature Review of Cutaneous Melanoma trials Research Report on Cutaneous Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma | Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 28 | 2027-06-01 | 2026-09-08 |
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma Wide Local Excision - Cutaneous Melanoma, Stage II, Cutaneous Melanoma | Not applicable | Not yet recruiting | University of Nebraska | 282 | 2026-12-24 | 2026-10-09 |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Opdualag, Nivolumab - Cutaneous Melanoma, Melanoma Stage IV | Phase 2 | Recruiting | University Health Network, Toronto | 54 | 2026-11-30 | 2026-10-13 |
| A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors KUP-101A - Cutaneous Melanoma, Mucosal Melanoma | Phase 1 | Recruiting | Kupando GmbH | 21 | 2026-07-03 | 2026-08-12 |
| Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography - Cutaneous Melanoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 428 | 2026-04-17 | 2026-09-24 |
| Phase 1 Study of PF-08046033 in Advanced Solid Tumors PF-08046033 - Non-Small-Cell Lung, Esophageal Cancer | Phase 1 | Recruiting | Pfizer | 250 | 2026-04-08 | 2026-10-13 |
| Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg - Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Recruiting | Melanoma Institute Australia | 494 | 2026-02-09 | 2026-02-19 |
| Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma Blood Sample, Health Related Quality of Life Questionnaires (HRQoL), Medical Chart Review - Cutaneous Melanoma, Cutaneous Melanoma, Stage III | Recruiting | University of California, San Francisco | 300 | 2025-10-13 | 2025-11-10 | |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2 / Phase 3 | Recruiting | Linnaeus Therapeutics, Inc. | 135 | 2025-08-06 | 2026-04-22 |
| Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) Acasunlimab, Pembrolizumab - Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) | Phase 2 | Terminated | Genmab | 1 | 2025-07-25 | 2026-09-30 |
| ACTengine® IMA203 Combined With mRNA-4203 IMA203, mRNA-4203 - Cutaneous Melanoma, Synovial Sarcoma | Phase 1 | Recruiting | Immatics US, Inc. | 15 | 2025-07-25 | 2026-01-08 |
| Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: - Urothelial Carcinoma, Renal Cancer | Not applicable | Recruiting | Institut Claudius Regaud | 450 | 2025-07-23 | 2026-06-15 |
| Melanoma of the Skin and Exposure to Solar Ultraviolet Radiation at Work in Modena Territory: a Case-control Study to Promote an Active Search and Prevention of Occupational Diseases Based on Recent INAIL Criteria Skin Melanoma, Cutaneous Melanoma | Recruiting | University of Modena and Reggio Emilia | 300 | 2025-07-07 | 2025-12-18 | |
| NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma Anti-PD1 Therapy Timing - Cutaneous Melanoma | Recruiting | AC Camargo Cancer Center | 250 | 2025-04-23 | 2026-07-02 | |
| 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors 177Lu-RAD204 - PDL1 Gene Mutation, Non Small Cell Lung Cancer | Early Phase 1 | Recruiting | Radiopharm Theranostics, Ltd | 30 | 2024-06-03 | 2026-02-19 |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy Exercise Test - Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma | Not applicable | Active not recruiting | AdventHealth Translational Research Institute | 12 | 2024-06-03 | 2026-03-25 |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma Defactinib, Avutometinib, Encorafenib - Cutaneous Melanoma, Brain Metastases | Phase 1 / Phase 2 | Recruiting | University of Utah | 33 | 2024-03-20 | 2025-12-03 |
| Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma Ultrasound Biomicroscopy - Cutaneous Melanoma | Not applicable | Terminated | Centre Hospitalier Universitaire de Nice | 1 | 2024-02-22 | 2026-06-18 |
| EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers Eutectic Mixture of Local Anesthetics, Placebo Administration, Questionnaire Administration - Cutaneous Melanoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 100 | 2023-12-19 | 2026-03-10 |
Showing 20 of 77. Sign in to see all of them.
Melanoma (77) · Carcinoma, Non-Small-Cell Lung (14) · Uveal Melanoma (11) · Neoplasms (10) · Squamous Cell Carcinoma of Head and Neck (10) · Colorectal Neoplasms (9) · Carcinoma, Renal Cell (8) · Endometrial Neoplasms (6) · Neoplasm Metastasis (6) · Skin Neoplasms (6) · Triple Negative Breast Neoplasms (6) · Carcinoma, Merkel Cell (5) · Urinary Bladder Neoplasms (5) · Carcinoma, Ovarian Epithelial (4) · Esophageal Neoplasms (4)
Neoplasms by Histologic Type (77) · Neoplasms by Site (77) · Neoplasms, Germ Cell and Embryonal (77) · Neoplasms, Nerve Tissue (77) · Neuroectodermal Tumors (77) · Neuroendocrine Tumors (77) · Nevi and Melanomas (77) · Skin Diseases (77) · Skin and Connective Tissue Diseases (77) · Skin Neoplasms (71) · Neoplasms (67) · Neoplasms, Glandular and Epithelial (20) · Carcinoma (17) · Lung Diseases (17) · Respiratory Tract Diseases (17)
pembrolizumab (15) · Nivolumab (10) · Ipilimumab (6) · Blood Specimen Collection (3) · Sentinel Lymph Node Biopsy (3) · Temozolomide (3) · relatlimab (3) · Dacarbazine (2) · Dermoscopy (2) · High-Energy Shock Waves (2) · Interleukin-2 (2) · Magnetic Resonance Spectroscopy (2) · Opdualag (2) · Watchful Waiting (2) · X-Rays (2)
Castle Biosciences Incorporated (2) · Dana-Farber Cancer Institute (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · M.D. Anderson Cancer Center (2) · OHSU Knight Cancer Institute (2) · Seagen Inc. (2) · A.J.M. van den Eertwegh (1) · AC Camargo Cancer Center (1) · AdventHealth Translational Research Institute (1) · Anaveon AG (1) · Ascentage Pharma Group Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Assistance Publique Hopitaux De Marseille (1) · Aulos Bioscience, Inc. (1) · Azienda Ospedaliero-Universitaria di Modena (1)
United States (54) · France (15) · Spain (15) · Canada (11) · Italy (10) · Germany (9) · Australia (8) · South Korea (6) · United Kingdom (6) · Belgium (3) · Denmark (3) · Switzerland (3) · Taiwan (3) · Brazil (2) · Poland (2)
Robert Cook, PhD (2) · Alberto Modenese, MD. PhD (1) · Amod Sarnaik, MD (1) · Andres Forero-Torres, MD (1) · Anu Gupta, MD (1) · Arash Yavari, MBBS (1) · Armelle Blondel, MD, PhD (1) · Arthur P. DeCillis, MD (1) · Bret Goodpaster, PhD (1) · Brittani K Seynnaeve (1) · Carlo M Contreras, MD (1)
PMID 34036233, PMID 34568719, PMID 22706980, PMID 26995019, PMID 28478931, PMID 28489678, PMID 28587288, PMID 28620382, PMID 29774030, PMID 30792021, PMID 31399043, PMID 31936897, PMID 32057276, PMID 32352425, PMID 33229456, PMID 34465599, PMID 35121932, PMID 35648432, PMID 35857579, PMID 36648215, PMID 36800443, PMID 36862181, PMID 38296197, PMID 38577337, PMID 40056460, PMID 40504479, PMID 40627813, PMID 40638872, PMID 40791544, PMID 41484629, PMID 41685950, PMID 41843333
2016 (2), 2025 (2), 2019 (1), 2023 (1), P30CA014089 (1), P30CA015704 (1), P50CA244289 (1), R00CA286967 (1), R01CA229261 (1), U01CA154967 (1), U10CA180820 (1), U10CA180886 (1)